Recent studies demonstrated that resveratrol, a grape-derived polyphenolic phytoalexin, could pharmacologically precondition (PC) the heart through a nitric oxide (NO)-dependent mechanism.
INTRODUCTION
Preconditioning-induced tolerance against myocardial ischemic reperfusion injury has been a subject of intensive investigation (13, 34) . Preconditioning may be achieved by pre-exposing the heart to a repetitive short exposure of ischemia or hypoxia followed by reperfusion or reoxygenation (ischemic or hypoxic preconditioning) (36, 12) , heat stress (30), oxidative stress (7) or chemical agents (pharmacological preconditioning) (43, 28) .
Resveratrol (trans-3, 4', 5-trihydroxystilbene), a naturally occurring polyphenolic compound abundantly found in grape skins, seeds and in wines, has been found to pharmacologically precondition the heart against ischemia/reperfusion injury (22, 35) . Recently, it has been found that resveratrol protects a variety of vital organs including kidney, heart, lung and brain from ischemia-reperfusion injury (18, 14) . Resveratrol possesses diverse biochemical and physiological actions for cellular protection, which includes estrogenic, anti-platelet and anti-inflammatory properties (3, 17) .
Adenosine is a potent intermediate of myocardial preservation. It shows its effects during the ischemia as well as during the reperfusion phases through receptor-mediated actions (9) .
There are four adenosine receptors A 1, A 2a, A 2b and A 3 (26) . Among the four, A 1 and/or A 3 receptors have been found to play a crucial role in cardio protection by virtue of their abilities to precondition the heart (42, 31) . Conflicting results exist in the literature when agonists of adenosine A 1 and A 2a receptors are used to precondition the heart (44, 1). More positive results were found with adenosine A 3 receptors. Activation of adenosine A 3 receptors reduces the degree of apoptosis produced by ischemia-reperfusion injury in the brain (11) and in the myocardium (39) .
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The objective of this study was to examine if the cardioprotective effects of resveratrol is realized through adenosine receptor activation. The results of the present study are in consistent with many previous reports that indicate the role of adenosine A 1 and A 3 receptors, but not A 2a receptor, in ischemic PC (33) . Initial studies with adenosine receptors implicated a role of adenosine A 1 receptor in PC (9) . Subsequent studies showed conflicting result, some of them demonstrating negative findings (1, 44) . However, recent studies clearly demonstrate involvement of adenosine A 3 receptors in PC (33) . The results indicate that resveratrol preconditions the heart through the activation of adenosine A 1 and A 3 receptors, the former transmitting a survival signal through PI-3-kinase-Akt-Bcl 2 signaling pathway, while the later protects the heart through a CREB-dependent BCL 2 pathway in addition to Akt-Bcl 2 pathway. . Sprague Dawley male rats weighing between 250-300 gms. were fed ad libitum regular rat chow with free access to water until the start of the experimental procedure. The rats were randomly assigned to one of the following groups ( Figure 1 ): perfused for 15 min with KHB with i) vehicle only; ii) 1 µM CPT, iii) 1 µM CSC, iv) 1 µM MRS 1191, v) 3 µM LY 294002, vi) KHB containing 10 µM resveratrol; vii) 10 µM resveratrol + 1 µM CPT; viii) 10 µM resveratrol + 1 µM CSC; ix) 10 µM resveratrol + 1 µM MRS 1191; x) 10 µM resveratrol + 3 µM LY 294002,. All hearts were then subjected to 30 min ischemia followed by 2 h reperfusion.
MATERIALS AND METHODS

Resveratrol
Control experiments were performed with vehicle (DMSO) only, or CPT, CSC and MRS 1191 only.
Isolated working heart preparation. Rats were anesthetized with sodium pentobarbital (80 mg/kg, i.p.), (Abbott Laboratories, North Chicago, IL, USA) and anticoagulant with heparin sodium (500 IU/kg., i.v.) (Elkins-Sinn Inc., Cherry Hill, NJ, USA). After ensuring sufficient depth of anesthesia thoracotomy was performed, hearts were perfused in the retrograde Langendorff mode at 37 °C at a constant perfusion pressure of 100 cm of water (10 kPa) for a 5 min washout period. The perfusion buffer used in this study consisted of a modified KrebsHenseleit bicarbonate buffer (KHB) (in mM: sodium chloride 118, potassium chloride 4.7, calcium chloride 1.7, sodium bicarbonate 25, potassium bisphosphate 0.36, magnesium sulfate 1.2, and glucose 10). The Langendorff preparation was switched to the working mode following the washout period as previously described (12) .
At the end of 10 min, after the attainment of steady state cardiac function, baseline functional parameters were recorded. The circuit was then switched back to the retrograde mode and hearts were perfused either KHB with vehicle or any of the adenosine receptor blockers (Control), Resveratrol at a concentration of 10 µM or a combination of Resveratrol and adenosine receptors for a duration of 15 min. This was followed by a 5-min washout with KHB buffer, and then the hearts were subjected to global ischemia for 30 min and then 2 h of reperfusion. The first 10 min of reperfusion was in the retrograde mode to allow for post ischemic stabilization and there after, in the antegrade working mode to allow for assessment of functional parameters, which were recorded at 10-, 30-, 60-and 120-min reperfusion.
Cardiac function assessment. Aortic pressure was measured using a Gould P23XL pressure transducer (Gould Instrument Systems Inc., Valley View, OH, USA) connected to a side arm of the aortic cannula, the signal was amplified using a Gould 6600 series signal conditioner and monitored on a CORDAT II real-time data acquisition and analysis system (Triton Technologies, San Diego, CA, USA) (11) . Heart Rate (HR), Left Ventricular develops pressure (LVDP) (defined as the difference of the maximum systolic and diastolic aortic pressures), and the first derivative of developed pressure (dP/dT) were all derived or calculated from the continuously obtained pressure signal. Aortic flow (AF) was measured using a calibrated flow meter (Gilmont Instrument Inc., Barrington, IL, USA) and coronary flow (CF) was measured by timed collection of the coronary effluent dripping from the heart. Infarct size estimation. At the end of reperfusion, a 10 % (w/v) solution of triphenyl tetrazolium in phosphate buffer was infused into aortic cannula for 20 min at 37 °C (3). The hearts were excised and stored at -70 °C. Sections (0.8 mm) of frozen heart were fixed in 2% Para formaldehyde, placed between two cover slips and digitally imaged using a Microtek Scan Maker 600z. To quantitative the areas of interest in pixels, a NIH image 5.1 (a public-domain software package) were used. The infarct size was quantified and expressed in pixels. 
RESULTS
Effects of Resveratrol on Myocardial Function. There were no differences in baseline function between six groups. In general, there were no significant differences between resveratrol vs. control and also Resveratrol+A 1 , Resveratrol+A 2a or Resveratrol + A 3 vs.
Resveratrol on heart rates and coronary flow ( Table I) . As was expected, on reperfusion, the absolute values of all functional parameters were decreased in all the groups as compared with the respective baseline values. Group II (Resveratrol) displayed significant recovery of post ischemic myocardial function. The cardio protective effects of resveratrol were evidenced by significant differences in the LVDP from R-30 onwards (Table I) , the difference is especially apparent at R-60 and at R-120 and also in the LVdp/dt at R-120. Aortic flow was markedly higher in the resveratrol group from R-30 onwards at the all rest three points. R-30, R-60 and R-120 . With the use of Adenosine A 1 (CPT) and A 3 (MRS 1191) receptor inhibitors, resveratrol lost its cardio protective effects, which were evidenced by significant differences in the post ischemic period of LVDP from R-30 onwards; the decrease is prominent at R-60 and R-120 and also from the significant decrease of LVdp/dt at R-120. This is also confirmed from the Aortic flow value; which is markedly lower throughout the whole reperfusion period (Table I) .
LY294002 when used with Resveratrol, it partially abolished the cardio protective effect of Resveratrol, which were evidenced from LVDP from R-30 onwards; the decrease is more prominent at R-60 and also R-120. The same result also evidenced from LVdp/dt R-60 onwards;
the decrease is more prominent at R-120.
Effects of Resveratrol on Myocardial Infarct size.
Infarct size (percent of infarct vs. total area at risk) was noticeably reduced in resveratrol group as compared to the control (18.17±2.08% vs. 33.79±2.74%). This infarct zone was increased significantly when resveratrol was used along with CPT or MRS 1191, but not with CSC (20.1±1.6%). Thus, the infarct size was significantly higher in resveratrol + CPT and resveratrol+MRS1191 groups as compared to the resveratrol group (27.9±2.4% and 26.33±2.45%, respectively vs. 18.17±2.08%) as shown in the Figure 2 . Inhibition of PI-3-kinase with LY 294002 also increased the infarct size (24.9±2.3%) compared to resveratrol group.
Effects of Resveratrol on Cardiomyocyte Apoptosis
The percent of apoptotic cardiomyocytes was significantly reduced in resveratrol group as compared to the control (3.7±1.2% vs. 22.7±1.5%). This apoptotic cell death was increased significantly when resveratrol was used along with CPT or MRS 1191, but not with CSC. Thus, the apoptosis was significantly higher in resveratrol + CPT and resveratrol + MRS1191 groups as compared to the resveratrol group (11.3±1.7% and 23.3±1.6%, respectively vs. 
DISCUSSION
In the present study, we show that resveratrol exerts precondition-like effects on the pharmacologically precondition the heart (21, 23, 5). Ischemic preconditioning (PC) refers to the paradoxical mechanism by which cyclic episodes of brief reversible ischemia, each followed by another brief periods of reperfusion render the heart tolerant to subsequent ischemic reperfusion injury (13, 34, 36, 12) . PC is a complex phenomenon, which occurs through multiple interrelated partially blocked anti-ischemic effects of resveratrol, but almost completely eliminated its antiapoptotic properties. The reason for this was not clearly understood; however, it can be speculated that diverse survival signaling pathways exist for necrosis and apoptosis. It is well established that necrosis and apoptosis are independent contributors to myocardial infarction.
Thus, it is possible that adenosine A 3 receptor significantly contributes (greater than that by adenosine A 1 receptor) to resveratrol-mediated inhibition of necrotic cell death such that anti-infarction (which comprises effects due to necrosis plus apoptosis) effects of A 1 and A 3 receptors remain comparable.
The paradoxical nature of the data supporting complete dependence of the anti-apoptotic actions of A3 receptors, yet the observed reduction in this response with an A1 antagonist, may be due to non-selective inhibition of A3 receptors with CPT, as suggested by previous studies of even more selective A1 antagonists (25). There are reports that A1 receptors can indeed contribute to the anti-apoptotic effects, even more effectively than A3 receptors (20), which is in direct contrast to the current data supporting greater effects of A3 vs. A1 on apoptosis. Thus, the resveratrol effect may be unique. Another possible explanation could be due to inability of Tunel method to distinguish apoptosis from necrosis, and thus may lead to the overestimation of apoptosis. Tunel detects single-strand and double-strand DNA breaks with free 3'-OH termini and is thus nonspecific; apoptosis may occur without DNA fragmentation and cells can exhibit both internucleosomal DNA fragmentation and membrane damage typical of apoptosis and necrosis. It may be that these limitations and lack of distinction lead to an overestimation of apoptosis via Tunel, and therefore that the apparent A1 dependence stems from the anti-necrotic actions of the A1. Recently an alternative survival pathway via CREB that may bypass PI-3-kinase-Akt signaling was described. CREB phosphorylation was found to occur through the activation of the MAP kinase pathway via activation of p90rsk (15) . In a recent study, relaxin activated CREB through a Akt-independent signaling pathway (45), In this case, CREB may be phosphorylated via MEK/MAPK/p90rsk/CREB or cAMP-PKA signaling pathway, or both (41).
Akt is a critical regulator of PI-3-kinase-mediated cell survival (28)
In summary, the results of this study demonstrated that resveratrol preconditioning is mediated by both adenosine A 1 and A 3 receptors (Figure 8 ). While activation of A 1 and A 3 receptors is clearly linked with the survival signal mediated by Akt--Bcl 2 -Bad signaling pathway, the A 3 receptors also trigger another survival pathway mediated via CREB. Whether this survival pathway uses Akt (pathway 1 in Figure 8) or not (Pathway 2 in Figure 8 ) was not clear from the present study. However, the activation of CREB only through adenosine A 3 receptor, and not via A 1 receptor suggests that such activation may have occurred independent of Akt. Nevertheless, it appears that simultaneous activation of A 1 and A 3 receptors is required for resveratrol preconditioning suggesting that there may be cross talks between these two receptors during resveratrol preconditioning of the heart.
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The isolated hearts were pretreated for 15 min with 1µM CPT followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 1µM CSC followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 1µM MRS1191 followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 1µM LY294002 followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 10µM resveratrol followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 10µM resveratrol along with 1 µM CSC followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 10µM resveratrol along with 1 µM CPT followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 10µM resveratrol along with 1 µM MRS 1191 followed by 30 min ischemia and 2 h of reperfusion.
The isolated hearts were pretreated for 15 min with 10µM resveratrol along with 1 µM LY294002 followed by 30 min ischemia and 2 h of reperfusion. The isolated hearts were made globally ischemic for 30 min followed by 2 h of reperfusion.
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The isolated hearts were pretreated for 15 min with 10µM resveratrol along with 1 µM LY294002 followed by 30 min ischemia and 2 h of reperfusion. 
